Gatifloxacin and ethionamide as the foundation for therapy of tuberculosis.

Abstract

The use of gatifloxacin (GAT) in combination with ethionamide (ETA) with or without pyrazinamide (PZA) for a 12-week treatment period followed by an 8-week observation period was evaluated in a model of tuberculosis in mice. Mice treated with GAT at 300 mg/kg of body weight in combination with ETA (25 mg/kg) for 5 days per week had sterile lungs, whereas mice treated with GAT (100 mg/kg) and ETA (25 mg/kg) had about 10 CFU/lung; however, there was regrowth of the organisms in both groups at the end of the observation period. When PZA (450 mg/kg 5 days per week) was added to the high-dose GAT-ETA regimen, no viable mycobacteria were present after the 8-week observation period. GAT in combination with ETA and PZA has great promise for the treatment of tuberculosis.

• Authors: Michael H Cynamon, Mary Sklaney
• Journal: Antimicrobial agents and chemotherapy (Antimicrob Agents Chemother) Vol. 47 Issue 8 Pg. 2442-4 (Aug 2003) ISSN: 0066-4804 [Print] United States
• PMID: 12878502 (Publication Type: Journal Article, Research Support, U.S. Gov't, Non-P.H.S., Research Support, U.S. Gov't, P.H.S.)

Chemical References

• Anti-Infective Agents
• Antitubercular Agents
• Fluoroquinolones
• Gatifloxacin
• Ethionamide

Topics

• Administration, Intranasal
• Animals
• Anti-Infective Agents (therapeutic use)
• Antitubercular Agents (therapeutic use)
• Colony-Forming Units Assay
• Dose-Response Relationship, Drug
• Drug Resistance, Multiple, Bacterial
• Ethionamide (therapeutic use)
• Female
• Fluoroquinolones
• Gatifloxacin
• Lung (microbiology)
• Mice
• Mice, Inbred C57BL
• Mycobacterium tuberculosis (drug effects)
• Tuberculosis (drug therapy, microbiology)